☆ 4.5 Article

C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)

Related references

Note: Only part of the references are listed.

Article Oncology

Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab

Toshiki Kijima et al.

Summary: Early C-reactive protein kinetics were found to be associated with the survival of advanced urothelial cancer patients treated with pembrolizumab, with non-responder being an independent predictor for overall survival, along with liver metastasis and poor performance status. These findings suggest that early CRP kinetics could serve as a potential biomarker for identifying patients who may benefit from immune checkpoint inhibitors.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

David A. Braun et al.

Summary: The tumor immune microenvironment in clear cell renal cell carcinoma was investigated through single-cell RNA and T cell receptor sequencing, revealing an increase in terminally exhausted CD8(+) T cells and M2-like macrophages as the disease progresses. This immune dysfunction circuit is associated with a worse prognosis and identifies potential targetable immune inhibitory pathways in ccRCC.

CANCER CELL (2021)

Add to Collection

Article Oncology

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Kevin Bi et al.

Summary: The study shows that immune checkpoint blockade (ICB) remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations, critical for understanding response and resistance to ICB.

CANCER CELL (2021)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert Motzer et al.

Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

Shohei Fukuda et al.

Summary: The study found that the CRP flare-response group among mRCC patients was associated with significant tumor shrinkage and improved survival outcomes compared to the other two groups. Early CRP kinetics may be useful for evaluating the efficacy of nivolumab treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy

Chirag Krishna et al.

Summary: Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, and this study investigates the immune landscape of ccRCC using paired single-cell RNA (scRNA) and T cell receptor (TCR) sequencing, revealing extensive heterogeneity within and between patients. The study shows that tissue-resident T cells and tumor-associated macrophages (TAMs) are associated with responses to immune checkpoint blockade (ICB) and targeted therapies, highlighting the importance of cellular programs in therapeutic efficacy for ccRCC.

CANCER CELL (2021)

Add to Collection

Review Urology & Nephrology

A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma

Irbaz Bin Riaz et al.

Summary: This study established a living and interactive systematic review and network meta-analysis to maintain the best evidence for contemporary first-line treatment of metastatic renal cell carcinoma, including interactive tables of baseline characteristics and ranking data, as well as summaries of network meta-analysis results.

EUROPEAN UROLOGY (2021)

Add to Collection

Review Oncology

First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

Fahad Quhal et al.

Summary: The study performed indirect comparisons of first-line immune checkpoint inhibitor (ICI)-based combination therapies for metastatic renal cell carcinoma (mRCC), revealing the advantages and disadvantages of different therapeutic combinations. The findings suggest that combinations of ICIs and tyrosine kinase inhibitors (TKIs) may provide superior treatment options in the first-line setting, while ICI-ICI combinations could be optimal for tumors with increased PD-L1 expression.

EUROPEAN UROLOGY ONCOLOGY (2021)

Add to Collection

Review Urology & Nephrology

Checkpoint inhibitor immunotherapy in kidney cancer

Wenxin Xu et al.

NATURE REVIEWS UROLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

Kobe C. Yuen et al.

NATURE MEDICINE (2020)

Add to Collection

Article Oncology

C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study

Jakob M. Riedl et al.

CANCERS (2020)

Add to Collection

Article Oncology

Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer

Yuichi Ozawa et al.

MEDICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Oncology

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

A. Elkrief et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Immunology

Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer

Annett Schiwitza et al.

IMMUNOTHERAPY (2019)

Add to Collection

Article Oncology

Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma

Hiroki Ishihara et al.

TARGETED ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

Yosuke Yasuda et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Urology & Nephrology

Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy

Charis Kalogirou et al.

UROLOGIA INTERNATIONALIS (2017)

Add to Collection

Article Oncology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

I. Puzanov et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

Add to Collection

Review Oncology

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Geoffrey T. Gibney et al.

LANCET ONCOLOGY (2016)

Add to Collection

Review Urology & Nephrology

C-reactive protein as a biomarker for urological cancers

Kazutaka Saito et al.

NATURE REVIEWS UROLOGY (2011)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Urology & Nephrology

Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma

Kazutaka Saito et al.

EUROPEAN UROLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.